Publicacions en col·laboració amb investigadors/es de Rush University Medical Center (115)

2024

  1. Anticoagulation Use and Endovascular Thrombectomy in Patients with Large Core Stroke: A Secondary Analysis of the SELECT2 Trial

    Annals of Neurology, Vol. 96, Núm. 5, pp. 887-894

  2. Clinical relevance of intracranial hemorrhage after thrombectomy versus medical management for large core infarct: a secondary analysis of the SELECT2 randomized trial

    Journal of NeuroInterventional Surgery, pp. 1-8

  3. Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients with Large Ischemic Strokes: A Prespecified Analysis of the SELECT2 Trial

    JAMA Neurology, Vol. 81, Núm. 4, pp. 327-335

  4. Endovascular Thrombectomy for Large Ischemic Stroke Across Ischemic Injury and Penumbra Profiles

    JAMA, Vol. 331, Núm. 9, pp. 750-763

  5. Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial

    The Lancet, Vol. 403, Núm. 10428, pp. 731-740

  6. Pathology-based brain arterial disease phenotypes and their radiographic correlates

    Journal of Stroke and Cerebrovascular Diseases, Vol. 33, Núm. 6

  7. Predictors of anastomotic leak and conduit necrosis after oesophagectomy: Results from the oesophago-gastric anastomosis audit (OGAA)

    European Journal of Surgical Oncology, Vol. 50, Núm. 6

2023

  1. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts

    International Journal of Molecular Sciences, Vol. 24, Núm. 20

  2. Expanded and Independent Spanish Validation of the MDS-Non Motor Rating Scale

    Movement Disorders Clinical Practice, Vol. 10, Núm. 4, pp. 586-595

  3. Trial of Endovascular Thrombectomy for Large Ischemic Strokes.

    New England Journal of Medicine, Vol. 388, Núm. 14, pp. 1259-1271

2022

  1. Melphalan flufenamide for relapsed/refractory multiple myeloma

    Drugs of today (Barcelona, Spain : 1998), Vol. 58, Núm. 8, pp. 407-423

  2. Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL

    Leukemia and Lymphoma, Vol. 63, Núm. 9, pp. 2063-2073

  3. Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

    British Journal of Haematology, Vol. 196, Núm. 3, pp. 639-648

  4. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1999-2012.e6

  5. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2025-2038.e1

  6. Thrombectomy versus Medical Management in Mild Strokes due to Large Vessel Occlusion: Exploratory Analysis from the EXTEND-IA Trials and a Pooled International Cohort

    Annals of Neurology, Vol. 92, Núm. 3, pp. 364-378

2021

  1. Decline in subarachnoid haemorrhage volumes associated with the first wave of the COVID-19 pandemic

    Stroke and Vascular Neurology, Vol. 6, Núm. 4, pp. 542-552

  2. Global impact of COVID-19 on stroke care

    International Journal of Stroke, Vol. 16, Núm. 5, pp. 573-584

  3. Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection

    BJS Open

  4. Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: The COVIDSurg mortality score

    British Journal of Surgery, Vol. 19, Núm. 4